Jugulete G, Mardarescu M, Petrea S, Dragan MI, Luminos ML; International Conference on AIDS (15th : 2004 : Bangkok, Thailand).

Int Conf AIDS. 2004 Jul 11-16; 15: abstract no. TuPeB4441.

Infectious Diseases Institute 'Matei Bals', Bucharest, Romania

Background: There are 5043 HIV-infected children registered on Romaine Public Health Ministry. In our clinic we have registered than 700 HIV - infected children, 90% are treated antiretroviral therapy (ARV). Approximate 80% from HIV-infected children; have been treated with three antiretroviral drugs (HAART). Objective: To evaluate efficacy and tolerability of various regimens with lopinavir/ritonavir in HIV-infected children. Methods: We have monitorised clinical and laboratory (CD4 cell count, viral load and biochemical parameters) 100 HIV infected children, with ages between 9 -14 years old, for 96 weeks. The children, with various stages of disease (A3-5, B1-9, B2-21, B3-40, C1-10, C2-8, and C3-7) were treated with Kaletra plus two nucleoside reverse transcriptase inhibitor (NRTI) - 89 children and Kaletra plus one NRTI plus one non-nucleoside reverse transcriptase inhibitor (NNRTI) - 11 children. Results: Overall the therapy was generally well tolerated for the duration of study. All patients were survived at 96 week of study. Adverse reactions (rash, nausea, vomiting, abdominal pain, and headache) and opportunistic infections were rare. We have observed discreet sings of lipodysrtophy at both lots. One patient was tacked or the study because he was presented one major adverse reaction at one week of therapy with 2 NRTI's + lopinavir/ritonavir (thrombocytopenia) and one child have presented reversible hyponatremia. At weeks 96 of therapy, mean CD4-cell count increased by 180 cells/mm3 on group treated with 2NRTI's + lopinavir/ritonavir and 155 cells/mm3 on group treated with NRTI + NNRTI +lopinavir/ritonavir. After weeks 96 of therapy, VL declining<400 copies/ml at 70% from children's first group and 60% from group two. We have observed metabolic abnormalities at 15% of patients. Conclusions: All combinations of lopinavir/ritonavir have very good efficacy and tolerability in naive and experienced HIV - infected children. HAART brings one categorically benefit form HIV infected children survival duration and quality of live.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• Child
• Drug Therapy, Combination
• HIV Infections
• HIV Seropositivity
• Humans
• Pyrimidinones
• Reverse Transcriptase Inhibitors
• Ritonavir
• Viral Load
• drug therapy
• lopinavir
• therapy

Other ID:

• GWAIDS0038048

UI: 102282264

From Meeting Abstracts